Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tevogen Bio Holdings ( (TVGN) ) just unveiled an announcement.
On January 28, 2025, Tevogen Bio Holdings Inc. announced it received an initial $2 million grant from KRHP LLC, with the potential for an additional $8 million in non-dilutive funding, to support the development of T cell therapeutics for cancers and viral infections. The grant will also aid in expanding the company’s artificial intelligence efforts, Tevogen.AI, and comes alongside a previously announced $36 million loan agreement, reflecting the company’s strategic focus on efficient operations and innovation.
More about Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech company focused on developing off-the-shelf, genetically unmodified precision T cell therapies for treating infectious diseases, cancers, and neurological disorders. The company harnesses CD8+ cytotoxic T lymphocytes to address significant unmet needs of large patient populations and emphasizes sustainability and commercial success through patient accessibility, advanced science, and innovative business models.
YTD Price Performance: 58.49%
Average Trading Volume: 3,772,101
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $236.3M
For a thorough assessment of TVGN stock, go to TipRanks’ Stock Analysis page.
